CD8A and cancer: However, in a retrospective analysis, McGrail D.J. et al. showed that in cancer patients with no positive correlation between neoantigen load (a TMB surrogate) and CD8+ T-cell levels, a high TMB was not a predictive biomarker of ICI therapy.